Combining Panel-Based Next-Generation Sequencing and Exome Sequencing for Genetic Liver Diseases - 05/07/23
Abstract |
Objectives |
To determine how advanced genetic analysis methods may help in clinical diagnosis.
Study design |
We report a combined genetic diagnosis approach for patients with clinical suspicion of genetic liver diseases in a tertiary referral center, using tools either tier 1: Sanger sequencing on SLC2SA13, ATP8B1, ABCB11, ABCB4, and JAG1 genes, tier 2: panel-based next generation sequencing (NGS), or tier 3: whole-exome sequencing (WES) analysis.
Results |
In a total of 374 patients undergoing genetic analysis, 175 patients received tier 1 Sanger sequencing based on phenotypic suspicion, and pathogenic variants were identified in 38 patients (21.7%). Tier 2 included 216 patients (39 of tier 1-negative patients) who received panel-based NGS, and pathogenic variants were identified in 60 (27.8%). In tier 3, 41 patients received WES analysis, and 20 (48.8%) obtained genetic diagnosis. Pathogenic variants were detected in 6 of 19 (31.6%) who tested negative in tier 2, and a greater detection rate in 14 of 22 (63.6%) patients with deteriorating/multiorgan disease receiving one-step WES (P = .041). The overall disease spectrum is comprised of 35 genetic defects; 90% of genes belong to the functional categories of small molecule metabolism, ciliopathy, bile duct development, and membrane transport. Only 13 (37%) genetic diseases were detected in more than 2 families. A hypothetical approach using a small panel-based NGS can serve as the first tier with diagnostic yield of 27.8% (98/352).
Conclusions |
NGS based genetic test using a combined panel-WES approach is efficient for the diagnosis of the highly diverse genetic liver diseases.
Le texte complet de cet article est disponible en PDF.Keywords : children, infant, jaundice, cholestasis, progressive familial intrahepatic cholestasis
Abbreviations : NGS, NICCD, PCR, PFIC, WES
Plan
This study was financially supported through grants from the Ministry of Science and Technology, Taiwan (109-2314-B-002-159-MY3), and National Taiwan University Hospital (107-S3917, 108-S4392). The authors have no conflicts of interest to disclose. |
Vol 258
Article 113408- juillet 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?